There is still much more to be learnt about cancer immunology, particularly what drives cancer cell growth, proliferation and resistance mechanisms, says Kevin Sin, Genentech's VP of oncology business development. Speaking to Scrip at the recent BIO-Europe Spring partnering conference, Sin describes Genentech's partnering strategy in oncology and how, almost a decade after the merger, Roche and Genentech are still working collaboratively and competitively to find the best new science in cancer.
Genentech's oncology deals VP outlines his data wishes & valuation methods for early-stage programs
Cancer therapy is changing too rapidly at present for it to make sense to have a strict partnering strategy listing specific areas to invest in, according to Genentech Inc.'s vice president of oncology business development Kevin Sin.
In an exclusive interview during the recent BIO-Europe Spring partnering event in Barcelona, March 20-22, Sin told Scrip that static...
Keep up with the top pharma business news of the week. On the go.
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.